Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 19,111

Document Document Title
WO/2014/118527A1
The present invention provides a topical composition comprising dantrolene and/or azumolene and one or more of a magnesium releasing compound and a compound which reacts with calcium ions under temperatures of 30 to 40 °C and pH levels ...  
WO/2014/120654A1
The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2014/119753A4
[Problem] To provide a therapeutic drug that exhibits a strong, selective inhibitory activity against myostatin, and enables muscle hyperplasia and an increase in muscle mass. [Solution] A peptide selected from (a)-(d), below, or a pharm...  
WO/2014/119634A1
The objective of the present invention is to develop and provide a novel muscle-building agent in which a muscle hypertrophy promoter and a muscle atrophy therapeutic agent are active ingredients, which can induce muscle building without...  
WO/2014/119649A1
 The objective of the present invention is to provide a compound, or a salt thereof, having regulatory activity on the function of lysophosphatidylserine receptors. The present invention provides a compound, or a salt thereof, having...  
WO/2014/119753A1
[Problem] To provide a therapeutic drug that exhibits a strong, selective inhibitory activity against myostatin, and enables muscle hyperplasia and an increase in muscle mass. [Solution] A peptide selected from (a)-(d), below, or a pharm...  
WO/2014/113878A1
A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic age...  
WO/2014/113875A1
The present invention provides a method for the stimulation of secretion or expression of muscular IL-6 in a subject with the administration of Protectin DX (PDX). Particularly, the increase in circulating levels of IL-6 originating from...  
WO/2014/113932A1
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I) or pharmaceutically acceptable salts thereof. (Formula I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compo...  
WO/2014/116981A1
[0001] The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention inclu...  
WO/2014/116845A1
The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...  
WO/2014/117155A9
The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes adm...  
WO/2014/117155A1
The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes adm...  
WO/2014/113784A1
The present invention relates to extracts of Sophora Flavascens, and compounds isolated therefrom for use in modulating airway smooth muscle contractility. Methods of creating enriched extracts of Sophora Flavascens are disclosed, as are...  
WO/2014/111580A1
A composition comprising a sufficient amount of urolithin B or a derivative thereof, for increasing muscle cell size.  
WO/2014/110291A1
Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and d...  
WO/2014/107566A1
Microparticles and nanoparticles and compositions thereof are provided. The microparticles and nanoparticles and compositions may be used for the treatment of musculoskeletal disease, such as osteoarthritis and injury such as trauma.  
WO/2014/106473A1
Disclosed is use of glycyrrhetinic acid or glycyrrhizic acid in preventing or treating radiation injury of soft tissue. Therefore, glycyrrhetinic acid or glycyrrhizic acid can be used for preparing medicaments for preventing or treating ...  
WO/2014/103410A1
An IGF-1 production promoter comprises, as an active ingredient: a Citrus depressa Hayata extract, preferably water and/or organic solvent extract of Citrus depressa Hayata fruit or leaves, a supercritical extract of Citrus depressa Haya...  
WO/2014/099904A1
Methods for enhancing motor function, enhancing functional status, and mitigating muscle weakness in a subject are provided. The methods utilize the combination of administering to the subject a nutritional composition comprising at leas...  
WO/2014/098249A1
The purpose of the present invention is to provide a composition having a tissue repairing activity that is capable of promoting a reaction relating to tissue repairing. Disclosed is a composition having an activity of repairing a tissue...  
WO/2014/089913A1
The present invention relates to a compound shown in a formula (I), a method for preparing the compound, a pharmaceutical composition containing the compound, and applications of the compound in preparing drugs for preventing and/or trea...  
WO/2014/092150A1
A peptide or pharmaceutically acceptable salt thereof selected from the group consisting of Ala-Hyp-Gly, Hyp-Gly-Pro, Leu-Hyp, Glu-Hyp, Gly-Pro-Hyp, Pro-Ala, Hyp-Gly, and Pro-Hyp having more excellent myoblast differentiation acceleratio...  
WO/2014/091446A1
The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.  
WO/2014/091020A1
The present invention refers to phenanthrene derivatives for use as medicaments, in the prevention and/or treatment of Myotonic Dystrophy Type 1, Huntington's Disease Like 2, Spinocerebellar Ataxia Type 8, Myotonic Dystrophy Type 2, Spin...  
WO/2014/086687A1
The present invention relates to the use of CFTR correctors in the treatment of genetic disorders affecting striated muscle selected from sarcoglycanopathies, Brody's disease (BD) and the recessive forms of Cathecolaminergic Polymorphic ...  
WO/2014/086243A1
Disclosed are a miRNA molecule for negatively regulating a type I interferon pathway and uses thereof, discovering that Has-miR-127-3p is closely related to systemic lupus erythematosus, and also verifying the target pathway of the miRNA...  
WO/2014/088106A1
A substance capable of binding to mSin3B, said substance exhibiting an analgesic effect on an ICS (intermittent cold stress) mouse, which is an experimental animal model of fibromyalgia, and, therefore, being useful as a prophylactic or ...  
WO/2014/087298A4
The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or –CR0 --, where R0 is hydrogen, C1 -C6 linear or branched chain alkyl, etc., Z is –CRe --, or, –N--, where Re is hydrogen, C1 -C6 linear or branched...  
WO/2014/087298A1
The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or –CR0 --, where R0 is hydrogen, C1 -C6 linear or branched chain alkyl, etc., Z is –CRe --, or, –N--, where Re is hydrogen, C1 -C6 linear or branched...  
WO/2014/089268A3
Described is an isolated somatic stem cell that is 2 to less than 6 micrometer in size and Lgr5+. Methods of preparing and using the cell are also described.  
WO/2014/084434A1
To prevent and treat a rotator cuff injury, the present invention provides a composition for preventing and treating a rotator cuff injury, containing cyanidin or delphinidin as an active ingredient.  
WO/2014/080286A3
This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanopartic...  
WO/2014/075135A1
The present invention relates to pharmaceutical compositions formulated for transmucosal delivery, and in particular sublingual delivery, comprising at least one tocotrienol or derivative thereof together with one or more pharmaceuticall...  
WO/2014/066964A1
The present Certificate of Addition relates to the use of pharmaceutical compositions containing a Mas receptor agonist, such as Angiotensin-(1-7), for treating degenerative muscular diseases.  
WO/2014/071131A1
The invention relates to methods for decreasing, inhibiting, preventing, or reducing calcification by inhibiting sortilin 1.  
WO/2014/071168A3
Methods and compositions useful for reducing loss of muscle function caused by bone metastasis in a subject with cancer. In certain embodiments, the methods of the present invention include administering to a cancer patient compositions ...  
WO/2014/065413A1
 A compound represented by general formula [I] or a pharmaceutically acceptable salt thereof. (In the formula, each symbol is as defined in the description.)  
WO/2014/065341A1
The present invent addresses the problem of providing a medicine for treating amyotrophic lateral sclerosis, a disease for which there is currently no effective therapeutic agent, and provides a therapeutic agent for amyotrophic lateral ...  
WO/2014/063602A1
Disclosed is a drug targeting delivery adjuvant, which is at least one selected from the group of pentoses selected from xylose and arabinose; hexoses selected from glucose, galactose, fructose and mannose; sugar alcohols selected from s...  
WO/2014/058000A1
The purpose of the present invention is to provide a 5-HT2B receptor antagonist which does not induce problematic adverse side effects or the like and can be used safely. Provided are a serotonin 2B receptor antagonist and a prophylactic...  
WO/2014/059013A1
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e...  
WO/2014/059403A1
Described herein are chimeric proteins, pharmaceutical compositions and methods for treating organophosphate exposure and poisoning (e.g., nerve agent poisoning, pesticide poisoning) in a subject (e.g., a human subject) and preventing or...  
WO/2014/053857A1
Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. Th...  
WO/2014/055905A1
Disclosed herein are methods for enhancing the efficacy of epigallocatechin gallate ("EGCg") in mitigating skeletal muscle loss in a subject. Providing EGCg to a subject in a nutritional composition reduces muscle protein degradation, th...  
WO/2014/054635A1
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  
WO/2014/054634A1
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  
WO/2014/048071A1
The present invention relates to a pharmaceutical composition of PRCP antagonist, PREP antagonist, or PRCP-PREP dual antagonist. The present invention also relates to a pharmaceutical composition jointly using PRCP antagonist and mTOR an...  
WO/2014/051398A1
The present invention relates to a composition for promoting differentiation of myoblast, comprising Acecainide or Procainamide which is a derivative of Acecainide, or pharmaceutically acceptable salts of Acecainide, to a method for prom...  
WO/2014/049841A1
The objective of the present invention is to provide a new medicinal use of clarithromycin. The present invention is a therapeutic agent or a preventive agent for meibomian gland dysfunction or meibomian gland blockage and comprises clar...  

Matches 251 - 300 out of 19,111